Abhimanyu Verma Sells 5,285 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Posted by Brenda Bartman on Jul 7th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) CTO Abhimanyu Verma sold 5,285 shares of the stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.10, for a total value of $26,953.50. Following the transaction, the chief technology officer directly owned 192,171 shares in the company, valued at approximately $980,072.10. The trade was a 2.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Stock Up 1.9%

NASDAQ SOPH traded up $0.10 during trading hours on Tuesday, hitting $5.44. 284,563 shares of the company were exchanged, compared to its average volume of 187,273. The company has a 50 day moving average of $5.12 and a two-hundred day moving average of $4.96. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a 52-week low of $2.92 and a 52-week high of $6.30. The firm has a market cap of $456.36 million, a price-to-earnings ratio of -10.46 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million.

Institutional Trading of SOPHiA GENETICS

Several large investors have recently modified their holdings of the business. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS during the third quarter valued at approximately $49,000. Perkins Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 4th quarter worth $49,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS during the first quarter worth $50,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter valued at $55,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SOPH has been the topic of a number of recent research reports. BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.50.

Check Out Our Latest Research Report on SOPHiA GENETICS

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

Negative Sentiment: Chairman Jurgi Camblong sold 22,486 shares under a pre-arranged Rule 10b5-1 plan, and several other executives also sold stock the same day, including the CEO, CFO, CTO, and other insiders. While these sales were reportedly tied to tax withholding from vested equity awards, the breadth of selling can still pressure investor sentiment. Article: Chairman Jurgi Camblong sale filing
Neutral Sentiment: The insider transactions were disclosed as routine 10b5-1 sales related to equity-award vesting, which makes them less concerning than discretionary selling, but they still add noise around the stock. Article: Philippe Menu sale filing
Neutral Sentiment: SOPHiA GENETICS previously reported quarterly revenue of $21.69 million, topping expectations, even though earnings missed estimates. That mixed report still supports the stock’s broader recovery from its lows. Previous earnings report referenced in background

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.